293 related articles for article (PubMed ID: 22460389)
1. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.
Li X; Ling W; Khan S; Yaccoby S
J Bone Miner Res; 2012 Aug; 27(8):1635-48. PubMed ID: 22460389
[TBL] [Abstract][Full Text] [Related]
2. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Li X; Ling W; Pennisi A; Wang Y; Khan S; Heidaran M; Pal A; Zhang X; He S; Zeitlin A; Abbot S; Faleck H; Hariri R; Shaughnessy JD; van Rhee F; Nair B; Barlogie B; Epstein J; Yaccoby S
Stem Cells; 2011 Feb; 29(2):263-73. PubMed ID: 21732484
[TBL] [Abstract][Full Text] [Related]
3. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.
Atsuta I; Liu S; Miura Y; Akiyama K; Chen C; An Y; Shi S; Chen FM
Stem Cell Res Ther; 2013; 4(5):111. PubMed ID: 24025590
[TBL] [Abstract][Full Text] [Related]
5. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
[TBL] [Abstract][Full Text] [Related]
6. Role of decorin in the antimyeloma effects of osteoblasts.
Li X; Pennisi A; Yaccoby S
Blood; 2008 Jul; 112(1):159-68. PubMed ID: 18436739
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.
Tsukamoto S; Løvendorf MB; Park J; Salem KZ; Reagan MR; Manier S; Zavidij O; Rahmat M; Huynh D; Takagi S; Kawano Y; Kokubun K; Thrue CA; Nagano K; Petri A; Roccaro AM; Capelletti M; Baron R; Kauppinen S; Ghobrial IM
Leukemia; 2018 Aug; 32(8):1739-1750. PubMed ID: 29925904
[TBL] [Abstract][Full Text] [Related]
8. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
[TBL] [Abstract][Full Text] [Related]
10. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
11. The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Lin HH; Hwang SM; Wu SJ; Hsu LF; Liao YH; Sheen YS; Chuang WH; Huang SY
PLoS One; 2014; 9(4):e94395. PubMed ID: 24722177
[TBL] [Abstract][Full Text] [Related]
12. Reversing bone loss by directing mesenchymal stem cells to bone.
Yao W; Guan M; Jia J; Dai W; Lay YA; Amugongo S; Liu R; Olivos D; Saunders M; Lam KS; Nolta J; Olvera D; Ritchie RO; Lane NE
Stem Cells; 2013 Sep; 31(9):2003-14. PubMed ID: 23818248
[TBL] [Abstract][Full Text] [Related]
13. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
14. Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment.
Carrancio S; Romo C; Ramos T; Lopez-Holgado N; Muntion S; Prins HJ; Martens AC; Briñón JG; San Miguel JF; Del Cañizo MC; Sanchez-Guijo F
Cell Transplant; 2013; 22(7):1171-83. PubMed ID: 23031585
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cell abnormalities in patients with multiple myeloma.
Garderet L; Mazurier C; Chapel A; Ernou I; Boutin L; Holy X; Gorin NC; Lopez M; Doucet C; Lataillade JJ
Leuk Lymphoma; 2007 Oct; 48(10):2032-41. PubMed ID: 17917971
[TBL] [Abstract][Full Text] [Related]
16. Wnt and BMP signaling pathways co-operatively induce the differentiation of multiple myeloma mesenchymal stem cells into osteoblasts by upregulating EMX2.
Wei XF; Chen QL; Fu Y; Zhang QK
J Cell Biochem; 2019 Apr; 120(4):6515-6527. PubMed ID: 30450775
[TBL] [Abstract][Full Text] [Related]
17. Decorin-Modified Umbilical Cord Mesenchymal Stem Cells (MSCs) Attenuate Radiation-Induced Lung Injuries via Regulating Inflammation, Fibrotic Factors, and Immune Responses.
Liu D; Kong F; Yuan Y; Seth P; Xu W; Wang H; Xiao F; Wang L; Zhang Q; Yang Y; Wang H
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):945-956. PubMed ID: 29976507
[TBL] [Abstract][Full Text] [Related]
18. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells.
Liu Z; Liu H; He J; Lin P; Tong Q; Yang J
Sci Signal; 2020 May; 13(633):. PubMed ID: 32457115
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and Prevents Glucocorticoid-Induced Osteoporosis.
Sui B; Hu C; Zhang X; Zhao P; He T; Zhou C; Qiu X; Chen N; Zhao X; Jin Y
Stem Cells Transl Med; 2016 Sep; 5(9):1238-46. PubMed ID: 27365487
[TBL] [Abstract][Full Text] [Related]
20. Development of an in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
